Skip to content

Depression research published in 2024

Page 17 of 26: studies 321 to 340 of 512, newest first. Back to the depression overview

Studies

Effect of intraoperative and/or postoperative esketamine administration on preventing postpartum depression: A systematic review and meta-analysis.

Psychiatry Research May 1, 2024 Jinping Wang, Hui Liu, Xinchuan Wei 9 citations

This systematic review and meta-analysis aimed to evaluate the impact of intraoperative and/or postoperative esketamine application on the prevention of postpartum depression (PPD). PubMed, Embase, and Web of Science were thoroughly searched for eligible randomized controlled trials (RCTs) regarding the application of esketamine for postnatal depression prevention. Nine RCTs including 1277...

DOI: 10.1016/j.psychres.2024.115890 (opens in new tab) Full text (opens in new tab) Ketamine Postnatal depression Maternal health Mental health treatment +3

Protocol for a randomised controlled trial of ketamine versus ketamine and behavioural activation therapy for adults with treatment-resistant depression in the community.

BMJ Open May 1, 2024 Ben Beaglehole, Richard Porter, Katie M. Douglas et al. 5 citations

Although short-term benefits follow parenteral ketamine for treatment-resistant major depressive disorder (TR-MDD), there are challenges that prevent routine use of ketamine by clinicians. These include acute dissociative effects of parenteral ketamine, high relapse rates following ketamine dosing and the uncertain role of psychotherapy. This randomised controlled trial (RCT) seeks to establish...

DOI: 10.1136/bmjopen-2024-084844 (opens in new tab) Full text (opens in new tab) Adult psychiatry Psychosocial intervention Depression treatment Ketamine therapy +2

Effects of ketamine on the severity of depression and anxiety following postoperative mechanical ventilation: a single-blind randomized clinical trial in Iran.

Acute and critical care May 1, 2024 Seyedbabak Mojaveraghili, Fatemeh Talebi, Sima Ghorbanoghli et al. 1 citation

In this study, we compare the effects of ketamine and the combination of midazolam and morphine on the severity of depression and anxiety in mechanically ventilated patients after discharge from the intensive care unit (ICU). This randomized single-blind clinical trial included 50 patients who were candidates for craniotomy and postoperative mechanical ventilation in the ICU of 5 Azar Teaching...

Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice.

Naunyn-Schmiedeberg's Archives of Pharmacology May 1, 2024 Rika Takaba, Daisuke Ibi, Keisuke Yoshida et al. 31 citations

Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT2A receptor (5-HT2A) activation. Recent studies have revealed that serotonergic psychedelics have therapeutic potential for neuropsychiatric disorders, including major depressive and anxiety-related disorders. However, the involvement of 5-HT2A in mediating the...

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

BMJ May 1, 2024 Athina-Marina Metaxa, Mike Clarke 78 citations

Abstract Objective To determine the efficacy of psilocybin as an antidepressant compared with placebo or non-psychoactive drugs. Design Systematic review and meta-analysis. Data sources Five electronic databases of published literature (Cochrane Central Register of Controlled Trials, Medline, Embase, Science Citation Index and Conference Proceedings Citation Index, and PsycInfo) and four...

DOI: 10.1136/bmj-2023-078084 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health treatment Depression therapy Clinical research +1

Repurposing Ketamine in the Therapy of Depression and Depression-Related Disorders: Recent Advances and Future Potential.

Aging and disease April 29, 2024 Qianting Deng, Emily Parker, Chongyun Wu et al. 8 citations

Depression represents a prevalent and enduring mental disorder of significant concern within the clinical domain. Extensive research indicates that depression is very complex, with many interconnected pathways involved. Most research related to depression focuses on monoamines, neurotrophic factors, the hypothalamic-pituitary-adrenal axis, tryptophan metabolism, energy metabolism, mitochondrial...

DOI: 10.14336/AD.2024.0239 (opens in new tab) Full text (opens in new tab) Mental health Depression treatment Ketamine therapy Antidepressants

Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon

Cancers April 27, 2024 Val Bellman 9 citations

Despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through Oregon’s Measure 109 in 2020, significant challenges have impeded its implementation. This review synthesizes the empirical data supporting the utilization of psilocybin therapy for addressing cancer-related depression, including an evaluation of its purported benefits and...

The mediation effects of nightmares and depression between insomnia and suicidal ideation in young adults

Scientific Reports April 26, 2024 Zixuan Guo, Xiaoli Han, Tiantian Kong et al. 8 citations

Suicide is prevalent among young adults, and epidemiological studies indicate that insomnia, nightmares, and depression are significantly associated with a high incidence of suicidal ideation (SI). However, the causal relationship between these factors and SI remains unclear. Therefore, the purpose of this study was to examine the association between nightmares and depression and insomnia and...

Application of mindfulness-based interventions – MBCT and MBSR – in depression treatment and relapse prevention

Quality in Sport April 25, 2024 Julia Szymonik, Sebastian Szopa

Introduction: Depression stands as a primary contributor to disability, prompting extensive exploration of treatment and prevention strategies. Recognizing the limitations of conventional approaches, the significance of effective non-pharmacological therapies, like psychotherapy, in managing mental health disorders is increasingly acknowledged. There's a growing interest in mindfulness-based...

A retrospective analysis of iv ketamine outcome on hospitalisations in an unselected psychiatric sample.

Acta Neuropsychiatrica April 25, 2024 Karl Sandström, Olli Kampman, Peter Asellus 1 citation

This study aims to explore the outcome with iv ketamine treatment in a real-world clinical setting, primarily measured as posttreatment days hospitalised. The psychiatric medical records of 46 patients having received iv ketamine on a psychiatric treatment indication between 2015 and 2018 were retrospectively examined. Analysis comparing the number and duration of hospital admissions before and...

Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023.

European Archives of Psychiatry and Clinical Neuroscience April 25, 2024 Li-Yuan Zhao, Guang-Fen Zhang, Xue-Jie Lou et al. 11 citations

Ketamine has demonstrated rapid and sustained antidepressant effects, marking its emergence as an innovative treatment of depression. Despite the growing number of preclinical and clinical studies exploring the antidepressant effects of ketamine and its enantiomers, a comprehensive bibliometric analysis in this field has yet to be conducted. This study employs bibliometric methods and...

A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of the Acute Antisuicidal and Antidepressant Effects of Intranasal (R,S)-Ketamine in Severe Unipolar and Bipolar Depression With and Without Comorbid Alcohol Use Disorder.

The Journal of Clinical Psychiatry April 24, 2024 Gregory H Jones, Courtney M Vecera, Ana C Ruiz et al. 13 citations

Objective: Although individuals with a family history of alcohol use disorder (AUD) have a superior antidepressant response to ketamine, outcomes in patients with current AUD remain unclear. This study sought to investigate whether intranasal (IN) racemic (R,S)-ketamine had antisuicidal and antidepressant effects in unipolar and bipolar depression and whether comorbid AUD conferred superior...

DOI: 10.4088/JCP.23m14974 (opens in new tab) Full text (opens in new tab) Depression Ketamine therapy Mental health treatment Substance abuse +1

EMBARK Mechanisms of Change in the Treatment of Depression

EMBARK Psychedelic Therapy for Depression April 23, 2024 Bill Brennan, Alex Belser

AbstractChapter 3 describes proposed psychological mechanisms of change within the EMBARK psychedelic therapy model for the treatment of depression. Twelve mechanisms of therapeutic change are described across the six EMBARK clinical domains: Existential–Spiritual: (a) spiritual self-development, (b) mystical experiences; Mindfulness: (c) freedom from rumination, (d) a more flexible identity,...

MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More

Psychiatric News April 23, 2024 Terri D’arrigo

announced in April that the Food and Drug Administration (FDA) approved the antipsychotic Fanapt (iloperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Iloperidone has been approved for the acute treatment of schizophrenia since 2009. The approval was based on a phase 3 clinical trial of 414 adults with a history of bipolar I disorder....

Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study.

Discover Mental Health April 17, 2024 Jon Berner, Animesh Acharjee 7 citations

Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In addition, novel antidepressants such as ketamine have sparse optimization evidence. Insights obtained from metabolomics may improve the management of patients. The objective of this study was to determine whether compounds in the cerebrospinal fluid (CSF)...

DOI: 10.1007/s44192-024-00066-5 (opens in new tab) Full text (opens in new tab) Depression treatment Personalized medicine Mental health research Biomarkers

Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.

Scientific Reports April 17, 2024 Jordan Sloshower, Richard J. Zeifman, Jeffrey Guss et al. 56 citations

Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). However, the mechanisms underlying its often persisting beneficial effects remain unclear. Observational research suggests that improvements in psychological flexibility may mediate therapeutic...

DOI: 10.1038/s41598-024-58318-x (opens in new tab) Full text (opens in new tab) Mental health treatment Depression research Mindfulness-based therapy Psilocybin therapy +1

Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression

Psychoactives April 16, 2024 Daniel Meling, Rebecca Ehrenkranz, Sandeep M. Nayak et al. 26 citations

Rationale: Psychedelic research re-emerged from a period of suppression into the so-called psychedelic renaissance. In parallel, most media reporting has shifted from the overstatement of the risks of psychedelics to overly positive hype. As the empirical evidence is more equivocal than frequently portrayed, the conclusions about the effectiveness of psychedelics should be considered...

DOI: 10.3390/psychoactives3020014 (opens in new tab) Psilocybin Misinformation Mood Psychotherapist +1

Ketamine for major depressive disorder during an inpatient psychiatric admission: Effectiveness, adverse events, and lessons learned.

Journal of Affective Disorders April 15, 2024 Benjamin D. Brody, Nana Park, Alexander Christian et al. 8 citations

Most studies examining the efficacy of ketamine for Major Depressive Disorder (MDD) have been conducted in outpatient or mixed inpatient/outpatient settings. Less is known about effectiveness and tolerability of ketamine for psychiatrically hospitalized patients. Efficacy and tolerability data from a naturalistic sample of acute inpatients may help inform institutions considering ketamine...

The effectiveness of online group mindfulness-based cognitive therapy for outpatients with depression in China.

Journal of Affective Disorders April 15, 2024 Jinjun Liu, Wei Duan, Zeping Xiao et al. 15 citations

With the development of online technology and the increase in real-world needs, conducting psychotherapy on online platforms has become a popular trend. The present study followed the schedule and content of Mindfulness-based Cognitive Therapy (MBCT), and only changed the treatment format (from offline to online) to investigate the effectiveness of online group MBCT for Chinese outpatients with...

Depression, an unmet health need in Africa: Understanding the promise of ketamine.

Heliyon April 15, 2024 Aletta Me Millen, William Mu Daniels, Sooraj Baijnath 6 citations

In Africa, there is currently a paucity of data on the epidemiology of depression, its treatment and management. The prevalence of depression is severely underestimated, with unique circumstances and societal risk factors associated with depression and its public awareness. Treating and managing depression is confounded by an inaccessibility to efficient and low-cost treatments for patients...

DOI: 10.1016/j.heliyon.2024.e28610 (opens in new tab) Full text (opens in new tab) Mechanism of action Mental health Psychopharmacology African healthcare +2